Walvax Biotechnology (300142.SZ): Freeze-dried herpes simplex virus mRNA vaccine approved for clinical trial.
Watson Biology (300142.SZ) announced that its subsidiaries, Beijing Watson Innovative Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., Yuxi Watson Biotechnology Co., Ltd., in collaboration with Fudan University and Shanghai Lanque Biomedical Co., Ltd. (referred to as "Lanque Biomedical"), have jointly developed and applied for clinical trials of a freeze-dried herpes zoster virus mRNA vaccine, and recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. After review, the freeze-dried herpes zoster virus mRNA vaccine accepted on September 18, 2025 meets the relevant requirements for drug registration and is approved to conduct clinical trials for the prevention of herpes zoster.
Walvax Biotechnology (300142.SZ) announced that its subsidiaries Beijing Watson Innovative Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., and Yuxi Walvax Biotechnology Technology Co., Ltd. have jointly developed a freeze-dried herpes zoster virus mRNA vaccine with Fudan University and Shanghai Lanque Biomedical Technology Co., Ltd. (referred to as "Lanque Biomedical"). The vaccine recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. After review, the freeze-dried herpes zoster virus mRNA vaccine, which was accepted for review on September 18, 2025, meets the relevant requirements for drug registration and is approved to conduct clinical trials for the prevention of herpes zoster.
Related Articles
HUAXIN CREDIT has granted a loan of RMB 27.5 million.
BANKCOMM (03328) will distribute a mid-term dividend of 1.563 yuan for every 10 shares on January 28th.
ZHENGYE INT'L (03363) plans to sell its subsidiary's assets in Zhongshan City for approximately 8.8074 million RMB.
HUAXIN CREDIT has granted a loan of RMB 27.5 million.
BANKCOMM (03328) will distribute a mid-term dividend of 1.563 yuan for every 10 shares on January 28th.
ZHENGYE INT'L (03363) plans to sell its subsidiary's assets in Zhongshan City for approximately 8.8074 million RMB.
RECOMMEND
Valued At $10 Trillion, The Largest IPO In History Is Coming As SpaceX Announces Listing Plan
12/12/2025
Five Imperatives And Eight Tasks: Central Meeting Specifies Next Year’s Economic Work, Highlights Identified
12/12/2025
Over 100 New Listings In Hong Kong This Year As Total Fundraising Tops HKD 270 Billion, Eighteen “A+H” Dual Listings
12/12/2025
